Biopharmaceutical Industry
Alnylam’s RNA interference drug wins favour of FDA AdCom
Alnylam’s Onpattro received a recommendation from an FDA advisory committee panel for a cardiomyopathy label expansion.
Alnylam’s Onpattro received a recommendation from an FDA advisory committee panel for a cardiomyopathy label expansion.